Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,060 | 537 | 85.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,020 | 1 | 9.6% |
| Education | $518.50 | 8 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,703 | 208 | $0 (2024) |
| Incyte Corporation | $1,689 | 27 | $0 (2024) |
| Janssen Biotech, Inc. | $942.31 | 48 | $0 (2024) |
| GENZYME CORPORATION | $758.74 | 38 | $0 (2024) |
| PFIZER INC. | $527.06 | 38 | $0 (2024) |
| LEO Pharma Inc. | $495.91 | 21 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $441.76 | 19 | $0 (2024) |
| Dermavant Sciences, Inc. | $439.14 | 16 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $421.77 | 30 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $405.27 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,899 | 209 | Incyte Corporation ($1,401) |
| 2023 | $3,300 | 181 | ABBVIE INC. ($783.01) |
| 2022 | $1,923 | 125 | ABBVIE INC. ($547.63) |
| 2021 | $475.56 | 31 | AbbVie Inc. ($168.48) |
All Payment Transactions
546 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Immunology | ||||||
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.51 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.38 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.87 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.17 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $6.55 | General |
| Category: Inflammation & Immunology | ||||||
| 12/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.61 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Incyte Corporation | OPZELURA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,020.00 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.76 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $6.88 | General |
| Category: DERMATOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $9.56 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: DERMATOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $25.36 | General |
| Category: Immunology | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.10 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $12.37 | General |
| Category: DERMATOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $7.51 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $21.41 | General |
| 11/19/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Monoclonal Antibody | ||||||
| 11/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $9.47 | General |
| Category: DERMATOLOGY | ||||||
| 11/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $29.33 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 461 | 863 | $77,996 | $23,865 |
| 2022 | 9 | 342 | 558 | $55,783 | $16,348 |
| 2021 | 10 | 307 | 467 | $47,627 | $14,352 |
| 2020 | 9 | 300 | 479 | $50,797 | $16,713 |
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 109 | 134 | $20,773 | $6,152 | 29.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 71 | 76 | $13,231 | $3,984 | 30.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 88 | 111 | $12,364 | $3,449 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 43 | $9,519 | $2,956 | 31.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $7,111 | $2,165 | 30.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 23 | 31 | $5,891 | $1,939 | 32.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 58 | 377 | $4,072 | $1,542 | 37.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 27 | 32 | $3,079 | $1,069 | 34.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 18 | 22 | $1,955 | $607.78 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 81 | 101 | $15,678 | $4,697 | 30.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 61 | 62 | $10,794 | $3,364 | 31.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 62 | 76 | $8,466 | $2,443 | 28.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $6,340 | $1,784 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 25 | $5,496 | $1,412 | 25.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 16 | 20 | $3,801 | $1,032 | 27.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 44 | 215 | $2,322 | $827.36 | 35.6% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 14 | 14 | $1,738 | $568.46 | 32.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 12 | $1,149 | $220.59 | 19.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 73 | 81 | $12,622 | $4,075 | 32.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 45 | 48 | $8,361 | $2,532 | 30.3% |
| 17000 | Destruction of skin growth | Office | 2021 | 51 | 60 | $6,686 | $1,652 | 24.7% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 23 | 27 | $5,133 | $1,542 | 30.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 25 | 25 | $4,798 | $1,338 | 27.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 14 | $3,100 | $926.48 | 29.9% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 17 | 21 | $1,867 | $687.78 | 36.8% |
About Sherri Howard, PA
Sherri Howard, PA is a Physician Assistant healthcare provider based in Bexley, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2012. The National Provider Identifier (NPI) number assigned to this provider is 1689927485.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sherri Howard, PA has received a total of $10,598 in payments from pharmaceutical and medical device companies, with $4,899 received in 2024. These payments were reported across 546 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($9,060).
As a Medicare-enrolled provider, Howard has provided services to 1,410 Medicare beneficiaries, totaling 2,367 services with total Medicare billing of $71,278. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Practice Information
- Specialty Physician Assistant
- Location Bexley, OH
- Active Since 10/18/2012
- Last Updated 09/11/2018
- Taxonomy Code 363A00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689927485
Products in Payments
- OPZELURA (Drug) $1,689
- RINVOQ (Biological) $1,502
- DUPIXENT (Biological) $1,062
- SKYRIZI (Biological) $1,028
- TREMFYA (Drug) $864.37
- VTAMA (Drug) $439.14
- ADBRY (Biological) $428.77
- TALTZ (Drug) $404.95
- Sotyktu (Drug) $391.85
- EUCRISA (Drug) $332.98
- CIBINQO (Drug) $194.08
- ILUMYA (Biological) $168.96
- COSENTYX (Drug) $145.74
- HUMIRA (Biological) $122.66
- Cimzia (Drug) $122.14
- Bimzelx (Biological) $108.41
- COSENTYX (Biological) $103.80
- REMICADE (Biological) $77.94
- Zoryve (Drug) $69.65
- YCANTH (Drug) $61.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.